SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
暂无分享,去创建一个
Byung Chul Kim | J. Bhak | Joong-Won Park | A. Shin | Yeon-Su Lee | S. Nam | Seung-hyun Hong | Jung-Ah Hwang | Bo Hyun Kim | J. A. Lee | Jin Sook Kim | Sung Hoon Lee | Bo Hyun Kim
[1] P. Dimond. Exceptional Responders: The “N of 1” Paradigm , 2014 .
[2] M. Meyerson,et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. , 2014, The Journal of clinical investigation.
[3] S. Gabriel,et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.
[4] J. Mainz,et al. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[5] M. Hediger,et al. Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. , 2013, Molecular aspects of medicine.
[6] P. Hrelia,et al. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. , 2013, Pharmacological research.
[7] A. Valéri,et al. CFTR p.Arg117His associated with CBAVD and other CFTR-related disorders , 2013, Journal of Medical Genetics.
[8] I. Choi,et al. Association Study between Folate Pathway Gene Single Nucleotide Polymorphisms and Gastric Cancer in Koreans , 2012, Genomics & informatics.
[9] Joong-Won Park,et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. , 2012, Journal of hepatology.
[10] Masatoshi Kudo,et al. Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population. , 2012 .
[11] J. Bruix,et al. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.
[12] Chiun Hsu,et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. , 2011, Journal of hepatology.
[13] Joong-Won Park,et al. Molecularly Targeted Therapies for Hepatocellular Carcinoma: Sorafenib as a Stepping Stone , 2011, Digestive Diseases.
[14] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[15] D. Thwaites,et al. Hijacking solute carriers for proton-coupled drug transport. , 2010, Physiology.
[16] S. Gabriel,et al. Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.
[17] Chih-Hung Hsu,et al. Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma , 2010, Cancer.
[18] L. Schwartz,et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] I. Borecki,et al. Genetic variants at the PDZ-interacting domain of the scavenger receptor class B type I interact with diet to influence the risk of metabolic syndrome in obese men and women. , 2009, The Journal of nutrition.
[20] S. Paggi,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[21] Nancy F. Hansen,et al. Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry , 2008, Nature.
[22] J. Lupski,et al. The complete genome of an individual by massively parallel DNA sequencing , 2008, Nature.
[23] C. Sawyers. The cancer biomarker problem , 2008, Nature.
[24] Ronald N Hines,et al. Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic Variants , 2007, Journal of Pharmacology and Experimental Therapeutics.
[25] E. Shephard,et al. Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3. , 2006, Mutation research.
[26] David E. Williams,et al. The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines , 2006, Drug metabolism reviews.
[27] R. Keep,et al. PEPT2 (Slc15a2)-Mediated Unidirectional Transport of Cefadroxil from Cerebrospinal Fluid into Choroid Plexus , 2005, Journal of Pharmacology and Experimental Therapeutics.
[28] Y. Cheung,et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. , 2005, British journal of clinical pharmacology.
[29] W. Sadee,et al. Genetic Variants of the Human H+/Dipeptide Transporter PEPT2: Analysis of Haplotype Functions , 2004, Journal of Pharmacology and Experimental Therapeutics.
[30] N. Chavez-Tapia,et al. Clinical practice guidelines: Management of Hepatocellular Carcinoma , 2014 .
[31] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[32] [Practice guidelines for management of hepatocellular carcinoma 2009]. , 2009, The Korean journal of hepatology.
[33] Minoru Kanehisa,et al. The KEGG database. , 2002, Novartis Foundation symposium.
[34] HighWire Press,et al. The journal of pharmacology and experimental therapeutics , 1909 .
[35] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.